Ted L. Liberti
COO & EVP of Business Development

EDUCATION:

M.B.A – University of Delaware: International

                  Corporate Strategy                           

MS – University of Delaware: Applied Economics                                                                             

BS – Penn State University: Economics

Fluent in French with a love for fine wine and French culture, Ted began his career in international banking with JP Morgan Paris to learn first-hand about financial markets and investment banking; knowledge he used while working at Immunicon to drive Immunicon’s business development, strategy, and finances. While at Immunicon Ted also helped form research projects and collaborations with bioMérieux S.A., Guerbet S.A. and French academic groups, and advised on the valuation of Immunicon’s MRI contrast agent patents, leading to a $750,000 licensing arrangement with Sweden’s Nycomed Pharmaceuticals.

From 2006 to 2012 Ted advised Ben Franklin Technology Partners’ portfolio of life science, medical device and IT early-stage companies on business development, marketing, finance and business strategy.

Ted Liberty oversees BioMagnetic Solutions business development, finance and strategic corporate partnering initiatives for cell & gene therapy, X-GRAFFE, FEOSS, biopharma and bioprocessing. He is well-versed in the company’s technologies, product development and manufacturing, and uses this knowledge to help build and expand BioMagnetic Solutions’ reach in the world of cell separations through corporate partnerships. He also oversees the intellectual property (IP) of BioMagnetic Solutions, as well as the NIH SBIR applications for funding.